Prime Therapeutics/Magellan Rx honors World Cancer Day, supports innovative oncology care

Prime is committed to closing gaps in cancer care by delivering meaningful oncology solutions to help people living with cancer.

February 2, 2024

Prime Therapeutics/Magellan Rx (Prime/MRx) joins the Union for International Cancer Control (UICC) in honoring World Cancer Day — a global awareness day dedicated to bringing attention, improving education and initiating action toward life-saving cancer treatment.

Since 2000, this initiative — held annually on Feb. 4 — gathers hospitals, health care organizations, providers, prescribers, patients and community-focused organizations to reduce the international impact of cancer. This year’s theme, “Close the Care Gap,” aims to ensure leaders prioritize cancer care, confront inequities and invest in resources for oncological care.

Prime/MRx is committed to helping cancer patients get the medicine they need to feel better and live well. Using an integrated model of care, Prime/MRx transforms the health care industry to provide patients with the same care they’d want for our loved ones.

“I really see Prime as an opportunity within the oncology world to really help drive programs, improve upon programs and create programs that would — at the end of the day — allow patients to receive the best care,” says Simone Ndujiuba, director, clinical strategy and innovation, oncology for Prime/MRx. Ndujiuba, a board-certified oncology pharmacist, shares industry news in Prime/MRx’s monthly Oncology Insights, which cover hot topics in cancer therapy. (Read the latest Oncology Insights.)

More than a million cancer cases are diagnosed each year, according to the American Cancer Society, which impacts patients, families and providers.

Hear from Simone Ndujiuba and Nathan Downhour about how Prime/MRx is working to simplify the experience and improve outcomes for the clients it serves

Related news

Stories

July 22, 2024

Introducing the latest issue of our medical and pharmacy benefit management report

The summer 2024 issue of the Magellan Rx Report provides insights on the industry’s most groundbreaking managed care solutions in some of the most complex areas of health care

Stories

July 18, 2024

Specialty drug trend forecasted to drop for employer groups, clinical experts say

Introduction of Humira® and Stelara® biosimilars contribute to continued decline in the autoimmune – anti-inflammatory trend

Stories

July 16, 2024

Prime/Magellan Rx earns top score on the Disability Equality Index

For the second consecutive year, Prime Therapeutics/Magellan Rx Management received a score of 100 on the Disability Equality Index®, which benchmarks disability workplace inclusion